Cargando…
The Clinicopathological Significance of Basal Markers in Early-Stage Invasive Carcinoma of No Special Type of the Breast
Objective: Basal markers [cytokeratin 5/6 (CK5/6) and epidermal growth factor receptor (EGFR)] are used in identifying the basal-like breast carcinoma subtype, which is associated with a poor prognosis. However, the clinicopathological significance in early-stage invasive carcinoma of no special typ...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Federation of Turkish Pathology Societies
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510611/ https://www.ncbi.nlm.nih.gov/pubmed/32364614 http://dx.doi.org/10.5146/tjpath.2020.01487 |
_version_ | 1785107990780575744 |
---|---|
author | Dirilenoğlu, Fikret Arıkan Etit, Demet Taşkaynatan, Halil Elmalı, Ferhan |
author_facet | Dirilenoğlu, Fikret Arıkan Etit, Demet Taşkaynatan, Halil Elmalı, Ferhan |
author_sort | Dirilenoğlu, Fikret |
collection | PubMed |
description | Objective: Basal markers [cytokeratin 5/6 (CK5/6) and epidermal growth factor receptor (EGFR)] are used in identifying the basal-like breast carcinoma subtype, which is associated with a poor prognosis. However, the clinicopathological significance in early-stage invasive carcinoma of no special type (IC, NST) has not been well established. Material and Method: In a five-year period, 133 female patients with early-stage IC, NST with a median follow-up time of 89 months were included. The immunohistochemistry-based molecular subtypes were identified according to ASCO/CAP guidelines in 2013. The cutoff values for basal positivity were determined as 10% for each marker. Results: Basal positivity was recorded in 83.3% (5/6) of triple-negative breast cancers, 50% (2/4) of HER2-enriched, 18.6% (13/70) of luminal B, and 8.3% of luminal A (4/48) subtype. CK5/6 and EGFR positivity were significantly associated with ER negativity (p < 0.001). EGFR positive cases were significantly associated with PR negativity and HER2 positivity compared to negative cases. However, basal positivity was not associated with the patient outcome (p = 0.006 and p = 0.004, respectively). Conclusion: Basal positive IC, NSTs were associated with hormone receptor negativity and HER2 overexpression; these patients would therefore be less likely to respond to hormonotherapy and more likely to benefit from anti-HER2 treatment as well as dual-kinase inhibitors. The lack of standardization of the definition of basal marker positivity may contribute to the conflicting results of prognostic studies. Hence, further studies focusing on developing a standard protocol for determining basal marker positivity are needed not only for IC, NST but also for other histological types of breast cancer. |
format | Online Article Text |
id | pubmed-10510611 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Federation of Turkish Pathology Societies |
record_format | MEDLINE/PubMed |
spelling | pubmed-105106112023-09-21 The Clinicopathological Significance of Basal Markers in Early-Stage Invasive Carcinoma of No Special Type of the Breast Dirilenoğlu, Fikret Arıkan Etit, Demet Taşkaynatan, Halil Elmalı, Ferhan Turk Patoloji Derg Original Article Objective: Basal markers [cytokeratin 5/6 (CK5/6) and epidermal growth factor receptor (EGFR)] are used in identifying the basal-like breast carcinoma subtype, which is associated with a poor prognosis. However, the clinicopathological significance in early-stage invasive carcinoma of no special type (IC, NST) has not been well established. Material and Method: In a five-year period, 133 female patients with early-stage IC, NST with a median follow-up time of 89 months were included. The immunohistochemistry-based molecular subtypes were identified according to ASCO/CAP guidelines in 2013. The cutoff values for basal positivity were determined as 10% for each marker. Results: Basal positivity was recorded in 83.3% (5/6) of triple-negative breast cancers, 50% (2/4) of HER2-enriched, 18.6% (13/70) of luminal B, and 8.3% of luminal A (4/48) subtype. CK5/6 and EGFR positivity were significantly associated with ER negativity (p < 0.001). EGFR positive cases were significantly associated with PR negativity and HER2 positivity compared to negative cases. However, basal positivity was not associated with the patient outcome (p = 0.006 and p = 0.004, respectively). Conclusion: Basal positive IC, NSTs were associated with hormone receptor negativity and HER2 overexpression; these patients would therefore be less likely to respond to hormonotherapy and more likely to benefit from anti-HER2 treatment as well as dual-kinase inhibitors. The lack of standardization of the definition of basal marker positivity may contribute to the conflicting results of prognostic studies. Hence, further studies focusing on developing a standard protocol for determining basal marker positivity are needed not only for IC, NST but also for other histological types of breast cancer. Federation of Turkish Pathology Societies 2020-09-15 /pmc/articles/PMC10510611/ /pubmed/32364614 http://dx.doi.org/10.5146/tjpath.2020.01487 Text en Copyright © 2020 The Author(s). https://creativecommons.org/licenses/by/4.0/This is an open-access article published by Federation of Turkish Pathology Societies under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Original Article Dirilenoğlu, Fikret Arıkan Etit, Demet Taşkaynatan, Halil Elmalı, Ferhan The Clinicopathological Significance of Basal Markers in Early-Stage Invasive Carcinoma of No Special Type of the Breast |
title | The Clinicopathological Significance of Basal Markers in Early-Stage Invasive Carcinoma of No Special Type of the Breast |
title_full | The Clinicopathological Significance of Basal Markers in Early-Stage Invasive Carcinoma of No Special Type of the Breast |
title_fullStr | The Clinicopathological Significance of Basal Markers in Early-Stage Invasive Carcinoma of No Special Type of the Breast |
title_full_unstemmed | The Clinicopathological Significance of Basal Markers in Early-Stage Invasive Carcinoma of No Special Type of the Breast |
title_short | The Clinicopathological Significance of Basal Markers in Early-Stage Invasive Carcinoma of No Special Type of the Breast |
title_sort | clinicopathological significance of basal markers in early-stage invasive carcinoma of no special type of the breast |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510611/ https://www.ncbi.nlm.nih.gov/pubmed/32364614 http://dx.doi.org/10.5146/tjpath.2020.01487 |
work_keys_str_mv | AT dirilenoglufikret theclinicopathologicalsignificanceofbasalmarkersinearlystageinvasivecarcinomaofnospecialtypeofthebreast AT arıkanetitdemet theclinicopathologicalsignificanceofbasalmarkersinearlystageinvasivecarcinomaofnospecialtypeofthebreast AT taskaynatanhalil theclinicopathologicalsignificanceofbasalmarkersinearlystageinvasivecarcinomaofnospecialtypeofthebreast AT elmalıferhan theclinicopathologicalsignificanceofbasalmarkersinearlystageinvasivecarcinomaofnospecialtypeofthebreast AT dirilenoglufikret clinicopathologicalsignificanceofbasalmarkersinearlystageinvasivecarcinomaofnospecialtypeofthebreast AT arıkanetitdemet clinicopathologicalsignificanceofbasalmarkersinearlystageinvasivecarcinomaofnospecialtypeofthebreast AT taskaynatanhalil clinicopathologicalsignificanceofbasalmarkersinearlystageinvasivecarcinomaofnospecialtypeofthebreast AT elmalıferhan clinicopathologicalsignificanceofbasalmarkersinearlystageinvasivecarcinomaofnospecialtypeofthebreast |